Court Turner
Venture Partner @ Avalon Ventures
Court Turner is a Series A investor at Avalon Ventures focused on Genetics and Wellness. Court R. Turner, J.D. joined Avalon Ventures in 2008 as an Advisor and became a Venture Partner in 2010. Mr. Turner is President, CEO and Director of Carolus Therapeutics, COO and Director of Afraxis, and Director of Zacharon Pharmaceuticals, each Avalon VIII portfolio companies. Additionally, Court led Avalon’s investment in RQx Pharmaceuticals asits founding CEO and Chairman; is COO and Director of Sova Pharmaceuticals; and a Board Observer of Cardeas Pharma, each Avalon IX portfolio companies.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Court Turner invests in
Stages Court Turner invests in
Countries Court Turner invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Genetics 1 (50%)
- Wellness 1 (50%)
- Health Care 1 (50%)
- Therapeutics 1 (50%)
- Biotechnology 1 (50%)
Stage
- Series A 1 (50%)
- Series B 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Synthorx is a biotechnology company using ground-breaking synthetic biology starting with our novel DNA base pair to discover and develop new protein therapeutics. The company uses new building blocks to create proteins that impart specificity not possible with native proteins. The result is treatments with improved efficacy, better safety, andbetter convenience for patients. Utilizing proprietary engineered organisms we have the ability to manufacture these improved proteins with high fidelity and the required yield for drug discovery and development. This unique platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies.The company was founded by Avalon Ventures based on important discoveries in Dr. Floyd Romesberg’s lab at The Scripps Research Institute in La Jolla, Calif. These discoveries include research published by the Romesberg lab in Nature, describing the first example of in vivo replication of a synthetic DNA base pair and the development of a semi-synthetic organism (read more here). Synthorx has the exclusive rights to this synthetic biology technology from The Scripps Research Institute. Investors include Avalon Ventures, Correlation Ventures, Medicxi, Orbimed, Osage University Partners, and RA Capital Management. | $10M / Series B / Jul 19, 2016 | ||
| Synthorx is a biotechnology company using ground-breaking synthetic biology starting with our novel DNA base pair to discover and develop new protein therapeutics. The company uses new building blocks to create proteins that impart specificity not possible with native proteins. The result is treatments with improved efficacy, better safety, andbetter convenience for patients. Utilizing proprietary engineered organisms we have the ability to manufacture these improved proteins with high fidelity and the required yield for drug discovery and development. This unique platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies.The company was founded by Avalon Ventures based on important discoveries in Dr. Floyd Romesberg’s lab at The Scripps Research Institute in La Jolla, Calif. These discoveries include research published by the Romesberg lab in Nature, describing the first example of in vivo replication of a synthetic DNA base pair and the development of a semi-synthetic organism (read more here). Synthorx has the exclusive rights to this synthetic biology technology from The Scripps Research Institute. Investors include Avalon Ventures, Correlation Ventures, Medicxi, Orbimed, Osage University Partners, and RA Capital Management. | $3.1M / Series A / Apr 21, 2014 |
Co-Investors
About Avalon Ventures
Avalon Ventures is an early stage venture capital fund focused on information technology and life sciences.
Avalon Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Court Turner
Venture Partner
|
|||
Kevin Kinsella
Founder and Managing Director
|
|||
Steve Tomlin
Managing Member
|
|||
Brady Bohrmann
Managing Member
|
|||
Richard Levandov
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Court Turner invest in?
Court Turner invests primarily in Genetics, Wellness and Health Care startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Court Turner?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Court Turner last invest?
The most recent investment recorded for Court Turner closed in Jul 2016. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
